Retroperitoneal sarcoma: a 10-year follow-up analysis using hospital-based cancer registry data in Japan.
Jpn J Clin Oncol
; 54(6): 716-721, 2024 Jun 01.
Article
en En
| MEDLINE
| ID: mdl-38411262
ABSTRACT
OBJECTIVES:
We sought clinical characteristics, survival outcomes, and prognostic factors for overall survival of retroperitoneal sarcoma in Japan.METHODS:
A Japanese hospital-based cancer registry database with a pivotal 10-year follow-up was used to identify and enroll patients, registered from 106 institutions, diagnosed with retroperitoneal sarcoma in 2008-2009. Treating hospitals were divided by hospital care volume; high-volume hospitals and low-volume hospitals were defined as ≥ 4 and < 4 cases/year, respectively.RESULTS:
A total of 91 men and 97 women were included, with a median age of 64 years. The most common histological type was liposarcoma in 101 patients, followed by leiomyosarcoma in 38 patients. The 5-year and 10-year overall survival rates were 44.1 and 28.3%. The majority of patients (n = 152, 80.9%) were treated at low-volume hospitals. High-volume hospital patients had higher 10-year overall survival rates than low-volume hospital patients (51.2% vs 23.2%, P = 0.026). Multivariate analysis revealed age over 60 years, treatment in low-volume hospitals and chemotherapy were independent predictors of unfavorable survival while treatment with surgery was an independent predictor of favorable survival.CONCLUSIONS:
The possibility of surgical removal was suggested to be the most important prognostic factor for retroperitoneal sarcoma. Better survival was shown in patients treated at high-volume hospitals in our series.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Neoplasias Retroperitoneales
/
Sarcoma
/
Sistema de Registros
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Asia
Idioma:
En
Revista:
Japanese journal of clinical oncology
/
Jpn J Clin Oncol
/
Jpn. j. clin. oncol
Año:
2024
Tipo del documento:
Article